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Eigil Kjeldsen1* and Anne Stidsholt Roug2Abstract
We here describe a novel unbalanced de novo translocation der(5)t(4;5)(q26;q21.1) in a 39-year-old male diagnosed
with acute T-cell lymphoblastic leukemia. Bone marrow (BM) was massively infiltrated with 85 % highly proliferative
polymorphic T-cell precursors. Immunologically, the malignant cells stained positive for CD7, CD34, intracytoplasmic
CD3+, TdT + and negative for CD3 and CD5. G-banded chromosome analysis of BM cells showed the normal
karyotype 46,XY[25] whereas BAC-based aCGH analysis revealed partial gain of 4q and partial loss of 5q. Multicolor
karyotyping confirmed the presence of an unbalanced der(5)t(4;5) as the sole structural abnormality. Subsequent
high-resolution oligonucleotide-based aCGH analysis showed that the der(5)t(4;5)(q26;q21.1) resulted in partial
trisomy of 4q26qter (117,719,015-190,613,014) and partial monosomy of 5q21.1qter (100,425,442-180,857,866) and
that there was no indication of any gene disruptions resulting from the breakages. Interphase FISH analysis using
BAC-based specific probes for 4q26 and 5q21.1 confirmed the breakpoints and revealed approximately 80 %
abnormal cells accordingly. At 4q26 the MIR1973 gene is located centromeric to the breakpoint in the copy number
neutral region and the TRAM1L1 gene is located within the gained region. At 5q21.1 the genes ST8SIA4 and
MIR548p are located centromeric to the breakpoint and no known genes up to approximately 1 Mb telomeric to
the breakpoint in the copy number loss region. Interestingly, only the gene ST8SIA4 at 5q21.1 have been implicated
in T-cell regulation as it encodes one of the key enzymes for polysialysation of surface proteins on dendritic cells
which are important regulators for T-cell proliferation. The der(5)t(4;5) is thought to play a crucial role in the
pathogenesis of acute T-ALL due to either gain of 4q, the loss of 5q, or deregulation of genes in proximity to the
breakpoints.
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Precursor T-lymphoblastic leukemia (T-ALL) accounts
for approximately 25 % of patients with adult acute
lymphoblastic leukemia and is a high-risk malignancy of
lymphocytes committed to the T-cell lineage [1]. It is a
heterogeneous disease and is diagnosed according to the
expression of specific cytoplasmic or surface markers.
The lymphoblasts are TdT positive and most often ex-
press CD3 and CD7. Moreover, variable expression of
CD1a, CD2, CD4, CD5 CD7 and CD8 and HLA-DR is
seen [2].* Correspondence: Eigil.Kjeldsen@ki.au.dk
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distribution, and reproduction in any mediumT-ALL has been associated with a normal karyotype in
30-45 % of cases [3,4]. Recurrent chromosomal translo-
cations are reported in 25-50 % [5]. The most frequent
abnormalities are del(6q), t(10;14). Translocations involv-
ing the TCR loci (14q11-TCRA/D and 7q34-TCRB) are
found in about 35 % of T-ALL/LBL. A high percentage
of cryptic abnormalities have been revealed by FISH
mainly cryptic deletions at 9p21 and 1p32. Cryptic
interstial deletion at 1p32 leading to SIL/TAL fusion
gene is found in 9-30 % of childhood T-ALL. Normal
karyotype and t(10;11)(q24;q11.2) are associated with
better survival whereas the presence of any derivative
chromosome is associated with poorer survival in child-
hood T-ALL [6].entral Ltd. This is an Open Access article distributed under the terms of the
creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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chromosomal abnormalities are characterized either by
fusion genes, as a consequence of reciprocal (balanced)
translocations such as t(15;17) and t(8;21), or by sole
genomic imbalances such as −5/del(5q), -7/del(7q) and
trisomy 8. In contrast, acquired recurrent unbalanced
translocations, which involve breakage and fusion of
non-homologous chromosomes either at the centro-
meres or somewhere along their arms, are relatively rare
in hematological malignancies. Unbalanced whole-arm
translocations, such as der(1;7)(q10;q10), der(7;12)(q10;
q10), der(9;18)(q10;q10) and der(3;10)(q10;q10) have
been reported as a sole and recurrent anomalies, indicat-
ing that they could be the primary changes [7-10]. The
most common of these are der(1;7)(q10;p10) which con-
stitute a distinct entity of myeloid malignancies [8]. The
clinical importance of other recurrent unbalanced
whole-arm translocations remains unsettled. Reportedly,
unbalanced whole-arm translocations are much more
common than unbalanced translocations involving non-
homologous chromosome arms. The most common is
der(19)t(1;19)(q23;p13) that is strongly associated with
precursor B-lymphoblastic leukemia (B-ALL) and can
exist in a balanced and in an unbalanced form both
resulting in a juxtaposition of PBX1 gene to TCF3 pla-
cing PBX1 under the transcriptional control of TCF3 on
der(19). Regarding prognosis, however, there is some
controversy whether the different forms affect clinical
outcome [11,12].
There are only few cytogenetic prognostic markers
described in T-ALL and the vast majority of these have
been identified through the characterization of transloca-
tions. We describe here a novel unbalanced de novo
translocation der(5)t(4;5) without additional chromo-
somal abnormalities in an adult diagnosed with T-ALL.
Case presentation
Clinical description
A 39-year-old male presented with a 5 weeks history of
universal lymphadenopathy, fever and symptoms of extra
hepatic cholestasis. Bone marrow (BM) examination was
consistent with acute T-cell lymphoblastic leukemia (T-
ALL) with an 85 % proportion of highly proliferative,
polymorphic T-cell precursors with high nuclear cyto-
plasmic ratio, staining CD3-, CD5-, CD7+, CD34+, intra-
cytoplasmic CD3+, and TdT+. PET-CT verified multi-
nodal and widespread extra-nodal involvement of disease
most prominent in the liver. Hematological examination
included a total white blood cell count of 4.26 x109/L,
hemoglobin of 7.7 mmol/L and, platelets of 222 x109/L.
G-banding of unstimulated cultured BM cells showed
a normal male karyotype 46,XY[25]. To check for sub-
microscopic aberrations associated with T-ALL, FISH
analysis for the following loci were performed: MLL, c-myc, bcr, TCF3 (all from DAKO, Denmark), SIL/TAL1,
and T-cell receptor loci α/δ, β and γ (all from Abbott
Molecular, Germany) of which all were negative.
The patient was initially treated with high dose steroid
followed by induction therapy according to the high-risk
arm of the NOPHO 2008 protocol. Minimal residual dis-
ease above the 5 % level was detected at day 29, which
entailed repeated and intensified induction therapy. Nine
and half months from initial diagnosis the patient died
from serious infections after high dose chemotherapy
while being in complete cytogenetic and hematological
remission.
Cytogenetic and molecular cytogenetic analyses
As part of a research program searching for submicro-
scopic genomic abnormalities in acute leukemia patients
with normal G-banded karyotypes the patient was sub-
jected to analysis by BAC-based aCGH analysis as
described [13]. This type of aCGH analysis can detect
genomic imbalances with a resolution about 1 Mb but
can not detect balanced chromosomal structural rearran-
gements and revealed two large genomic imbalances: an
appr. 72 Mb gain of chromosome 4 material from q26 to
q35.2 and an appr. 80 Mb region with loss of chromo-
some 5 material from q21.1q35.3 (data not shown).
To examine the cytogenetic basis for these findings,
and to disclose other possible structural balanced abnor-
malities, we then performed 24-color karyotyping using
24XCyte human multicolor FISH (mFISH) probe kit
according to manufacturer’s instructions (MetaSystems,
Altlussheim, Germany) consisting of 24 different
chromosome painting probes, each labeled with one of
five fluorochromosomes or a unique combination thereof
(combinatorial labeling). Image capture was done with
an automated Zeiss Axio Imager.Z2 equipped with a
CCD-camera (CoolCube1, MetaSystems) and appropriate
filters using Isis software. Karyotyping was done using
the 24-color mFISH upgrade package. Of 12 metaphases
analyzed, 7 were abnormal all harboring the unbalanced
translocation der(5)t(4;5) without additional structural
chromosomal abnormalities (Figure 1). Re-analysis of the
G-banding could not unequivocally identify the der(5)t
(4;5), which also remained cryptic upon analysis of
inverted gray scale image of the DAPI counterstain
image channel of positively identified translocation posi-
tive chromosomes (Figure 1B).
To map the break point regions (BPR) at 4q26 and
5q21.1 at the gene level, an oligonucleotide aCGH ana-
lysis was performed using CytoChip Cancer 4x180K v2.0
(BlueGnome, Cambridge, UK) encompassing a 20 kb
backbone with highest concentration of probes at 670
cancer genes. The analysis was done according to manu-
facturer’s instructions using 0,5 μg patient DNA. After
hybridization, washing and drying the oligo array was
Figure 1 24-color mFISH karyotyping (24XCyte). A. A representative 24-color mFISH karyogram showing the unbalanced der(5)t(4;5) (arrow) as
the sole cytogenetic abnormality. B. Single color gallery tool of normal chromosomes 4 and 5 and the unbalanced der(5)t(4;5). With this tool it is
possible to show assigned false colors (FC) representing individual color schemes of labeled chromosomes arranged in its capture sequence
(fluorescein isothiocyanate) FITC, (spectrum orange) SpO, (texas red) TR, (cyanine 5) Cy5, (7-Diethylaminocoumarin-3-carboxylic acid, succinimidyl
ester) DEAC, together with an inverted grayscale image of the (4',6-diamidino-2-phenylindole) DAPI image (Inv). The top panel shows a normal
chromosome 4 (#4) labeled with FITC, the middle panel shows a normal chromosome 5 (#5) labeled with SpO, and the bottom panel shows the
unbalanced der(5)t(4;5) harboring labels from both chromosome 4 and 5. With the inverted gray scale image of der(5) it is not possible to identify
the translocation.
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ner. Initial analysis and normalization was done with
BlueFuseMulti v2.6. For analysis and visualization nor-
malized log2 probe signal values were imported into
Nexus Copy Number software v. 6.1 (BioDiscovery, Cali-
fornia, USA) and segmented using FASST2 segmentation
algorithm with a minimum of 3 probes/segment. Regions
of gain or loss contained within copy number variable
regions (CNVs) were discarded. Reference genome was
NCBI build 36.1 (hg18). As expected, we found the two
large chromosomal imbalances: a partial gain of chromo-
some 4 from q26 to q35.2 (pos. 117,710,502-190,613,014)
and a partial loss of chromosome 5 q21.1 (pos. 100,418,842-
180,857,866) together with three minor copy number losses
(Figure 2). The analysis indicated that the breakpoint at
4q26 was between the oligo-ID’s A_16_P36882121 (pos.
117,710,502) and A_18_P14859960 (pos. 117,727,528) and
that the breakpoint at 5q21.1 was between the oligo-ID’s
A_16_P37295003 (pos.100,418,842) and A_16_P37295025
(pos. 100,432,041) (Figure 3A and B). To verify the break-
points, FISH analysis using BAC-based BlueFISH probes
(BlueGnome,Cambridge, UK) specific for the BPR were per-
formed. A dual-color FISH assay on metaphases with the
probes RP11-55 L3 (red) and RP11-36 M4 (green) specific
for 4q26 (Figure 3A) showed one fused signal at each of the
two normal chromosomes 4 and one green signal at the der
(5)t(4;5) (Figure 3C, left panel). Analyzing the relative red
and green fluorochrome intensities along the chromosome
axis on one of the normal chromosomes 4 and the der(5)t
(4;5), using the single color gallery tool in Isis (MetaSystems;
Altlussheim, Germany), revealed a small portion of the red-
labeled probe RP11-55 L3 present at der(5)t(4;5) (Figure 3C,right panel). This result strongly indicates that the break-
point is close to the one end of this probe and confirms the
breakpoint as uncovered by the oligo-based aCGH analysis.
The green-labeled FISH probe RP11-460O8 specific for
5q21.1 (Figure 3B) revealed that approximately 80 % of the
nuclei had one strong green signal and one minor green sig-
nal (1G1g pattern) (Figure 3D) while a minority of cells had
two equally strong signals (2G pattern). This result shows
that RP11-460O8 includes the breakpoint at 5q21.1 and
confirms the breakpoint identified by the oligo-based aCGH
analysis. Lack of material precluded further FISH analysis.
The breakpoints for the unbalanced translocation at
4q26 and at 5q21.1 is outside any known genes whereas
a couple of genes are located within 1,5 Mb of the break
points (Figure 3A and B, top). The MIR1973 gene is
located approximately 0,3 Mb centromeric for the break-
point at 4q26 in the copy number neutral region and the
TRAM1L1 gene is located approximately 1,4 Mb telo-
meric from the breakpoint within the gained region. At
5q21.1 the genes FAM174A, ST8SIA4 and MIR548p is
located up to 0,4 Mb centromeric from the breakpoint
and no known genes up to app. 1 Mb telomeric from the
breakpoint. From these data we concluded that there is
no apparent gene disruption and therefore it is unlikely
that the unbalanced translocation has resulted in a fusion
protein.
Discussion
Cytogenetic studies are useful in the clinical management
of leukemias and may also give clues to leukemogenesis as
cytogenetic changes associated with leukemias can hint to-
ward the genomic disorganization of malignant cells.
Figure 2 High-resolution array CGH reveals the unbalanced translocation der(5)t(4;5)(q26;q21.1) and three small copy number
alterations. To the right of the individual ideograms microarray profiles of copy number gains and losses are depicted. Gain is indicated by blue
color and loss is indicated by red color as an overlay on the ideogram. The log2 ratios for each chromosome are −2.5, 0, and +2.5 as illustrated for
chromosome 1. Red triangles indicate small copy number aberrations that are not known CNVs at 3q22.3 (pos. 140,098,965-140,157,676), Xp22.1
(pos. 24,674,165-24,767,944) and Xq21.1 (78,433,612-78,518,546).
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unbalanced karyotype 46,XY,der(5)t(4;5)(q26;q21.1)[13]/
46,XY[12]. To our knowledge the der(5)t(4;5) has not pre-
viously been described in the literature [14]. However, two
cases of peripheral T-cell lymphoma with reciprocal trans-
locations involving 4q26, t(4;16)(q26;p13) have been
reported. In one of these cases extended analyses showed
that the translocation resulted in rearrangement of inter-
leukin 2 gene but this gene is located at pos. 123,59 Mb at
4q27 [15,16]. There are no reported cases with transloca-
tions involving 5q21 [14]. Isolated trisomy 4 was reported
in 107 cases (2 ALL, 10 bi-lineage acute leukemia and the
rest mostly myeloid leukemias) with no reports on partial
trisomy 4q. Whole or partial monosomy 5 has been exten-
sively reported in myeloid disorders and only in two cases
of chronic lymphatic leukemia.
Unlike balanced reciprocal translocations, in which the
genes that become deregulated and the functional conse-
quences of the rearrangements can be readily identified
through analysis of the breakpoint regions, most chromo-
somal imbalances have functional consequences that are
unknown. This is mostly because the imbalances affectlarge genomic regions containing multiple genes and the
fact that tumors often have numerous unbalanced
chromosomal abnormalities. This degree of genetic com-
plexity has hampered delineation of the roles of individual
chromosomal gains and losses. Unbalanced translocations
between non-homologous chromosome arms are most
often part of complex karyotypes but rarely seen as sole
chromosomal aberrations making such cases important
for further studies. Although we did not clone the BPR or
investigate the gene expression the molecular cytogenetic
results provide important clues for further clinical and
diagnostic investigations. Gain of 4q or loss of 5q could re-
sult in a gene dosage effect.
Alternatively, sequences close to the BPR could inter-
fere with critical genes on either side of the break point
as in the case for der(19)t(1;19) in B-ALL [11,12]. In our
T-ALL patient we identified the BPR at 4q26 (pos.
117,710,502) with the genes MIR1973 and TRAM1L1
located on each side of the breakpoint, and the BPR
at 5q21.1 (pos. 100,418,842) with the genes FAM174A,
ST8SIA4 and MIR548p located centromeric to the
break point. The function of these genes is mainly
Figure 3 High-resolution array CGH reveals the breakpoints of the unbalanced translocation. Vertical blue lines indicate log2 ratios +0.24,
+0.60 and 2.50 and red lines indicate log2 ratios −0.24, -1.00 and −2.50. At the top are indicated location of genes, CNV’s and miRNA. The X-axes at the
bottom indicate chromosomal position. A. The break point at 4q26 was between the oligo-ID’s A_16_P36882121 (pos. 117,710,502) and A_18_P14859960
(pos. 117,727,528) (arrows). Blue shade indicates part of gained region. Location and size of the BAC probes RP11-55 L3 (red bar) and RP11-36 M4 (green
bar) are indicated. B. The break point at 5q21.1 was between the oligo-ID’s A_16_P37295003 (pos. 100,418,842) and A_16_P37295025 (pos. 100,432,041).
Red shade indicates part of lost region. Location and size of the BAC probe RP11-460O8 (green bar) is indicated. C. Left panel. Metaphase FISH using BAC
probes RP11-55 L3 (red) and RP11-36 M4 (green) showing two fused signals (normal chromosome 4) and one green signal on der(5)t(4;5). Right panel.
Single color gallery tool showing individual color schemes, orange (O) and green (G), and intensity measurements of each color channel (M). As can be
seen in the der(5)t(4;5) panel there is a weak red signal and a strong green signal showing that the break point is within RP11-55 L3. D. FISH using
RP11-460O8 (green) showing a nucleus with 1G1g pattern indicating that there is partial mono-allelic loss of the probe representing the break point.
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the key enzymes of biosynthesis of polysialic acid (PSA).
Interestingly, it was recently shown that polysialysa-
tion of surface proteins on dendritic cells influence
their T-lymphocyte interactions and that removal of
PSA from their surface promoted activation and prolif-
eration of T-lymphocytes [17].
The unbalanced der(5)t(4;5) as described in our case may
have arisen through three different mechanisms: 1) from a
balanced t(4;5) with initial loss of der(4) and subsequent
doubling of the remaining normal chromosome 4, 2) from
an initial trisomy 4 followed by translocation and loss of der
(4) or 3) from a translocation in G2 phase of the cell cycle,
with the der(4) and der(5) ending up in different daughter
cells followed by selective growth advantage. All three alter-
natives result in partial trisomy of 4q involving loci telo-
meric to MIR1973 and partial monosomy of 5q involving
loci telomeric to ST8SIA4.
Irrespective of the mechanism and what genes that are
affected, the unbalanced der(5)t(4;5) may confer prolif-
erative and growth advantages that contribute to neo-
plastic progression.Conclusion
We have described a novel unbalanced translocation
der(5)t(4;5)(q26;q21.1) as the sole cytogenetic abnor-
mality in a patient with de novo T-ALL. It is thought to
play a crucial role in the pathogenesis of acute T-cell
lymphoblastic leukemia either because of the gain of 4q,
the loss of 5q or deregulation of genes in proximity to
the BPR, as no apparent gene disruption was uncovered.
One explanation that this unbalanced translocation has
not been described previously could be that it is very
rare or more likely that it is underreported due to the
translocation’s cryptic nature. Further investigations are
necessary for clarification.
Consent
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